Difference between revisions of "Xu"
| Line 1: | Line 1: | ||
| − | <span style="font-size:x-large;">'''<span style="font-family: | + | <span style="font-size:x-large;">'''<span style="font-family:">Hyperbaric oxygenation may have reduced the incidence of sepsis associated with thermal burns.</span>'''</span> |
| − | '''<span style="font-family: | + | <span style="font-size:large;">'''<span style="font-family: " times="" new="" roman",="" serif;"="">Clinical Bottom Line:</span>'''</span> |
| − | <span style="font- | + | <span style="font-size:large;"><span style="font-family: " times="" new="" roman",="" serif;"="">1. Apparent reduction in the incidence of sepsis following thermal burns with the addition of hyperbaric oxygenation to a therapeutic regime.</span></span> |
| − | + | ---- | |
| − | ''' | + | '''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Citation: </span>'''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">1. Xu N, Li Z, Luo X. [Effects of hyperbaric oxygen therapy on the changes in serum sIL-2R and Fn in severe burn patients]. Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi 1999; 15(3):220-223. </span> <span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Lead author's name and fax:</span> |
| + | |||
| + | '''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Three-part Clinical Question:</span>''''' ''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">For patients with thermal burns, does the addition of hyperbaric oxygenation to a standard therapeutic regimen reduce the incidence of burn infection?</span> | ||
<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">'''Search Terms:''' Hyperbaric oxygenation, Burns thermal</span> | <span style="font-family: 'Times New Roman','serif'; font-size: 16px;">'''Search Terms:''' Hyperbaric oxygenation, Burns thermal</span> | ||
| − | '''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">The Study: </span>'''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Non-blinded randomised controlled trial with intention-to-treat unknown.</span> <span style="font-family: 'Times New Roman','serif'; font-size: 16px;"> | + | '''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">The Study: </span>'''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Non-blinded randomised controlled trial with intention-to-treat unknown.</span> |
| + | |||
| + | <span style="font-family: 'Times New Roman','serif'; font-size: 16px;">'''Study Patients:''' Patients with >30% body surface area burns (or 3rd degree >10%BSA).</span> | ||
| + | |||
| + | <span style="font-family: 'Times New Roman','serif'; font-size: 16px;">'''Control group''' (N = 17): Not stated</span> | ||
| + | |||
| + | <span style="font-family: 'Times New Roman','serif'; font-size: 16px;">'''Experimental group''' (N = 25): HBO regimen not stated</span> | ||
'''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">The Evidence:</span>''' | '''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">The Evidence:</span>''' | ||
| Line 19: | Line 27: | ||
|- | |- | ||
| style="width:146.35pt; border:solid windowtext 1.0pt" width="198" | | | style="width:146.35pt; border:solid windowtext 1.0pt" width="198" | | ||
| − | <span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family: | + | <span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">Non-Event Outcomes</span></span>'''</span> |
| − | | style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family: | + | | style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">Time to outcome</span></span>'''</span></p> |
| − | | style="width:76.5pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family: | + | | style="width:76.5pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">Control group</span></span>'''</span></p> |
| − | | style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family: | + | | style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">HBO group</span></span>'''</span></p> |
| − | | style="width:66.05pt; border:solid windowtext 1.0pt" width="91" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family: | + | | style="width:66.05pt; border:solid windowtext 1.0pt" width="91" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">P-value</span></span>'''</span></p> |
|- | |- | ||
| style="width:146.35pt; border:solid windowtext 1.0pt" width="198" | | | style="width:146.35pt; border:solid windowtext 1.0pt" width="198" | | ||
| − | <span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family: | + | <span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">Incidence of sepsis</span></span>'''</span> |
| − | | style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family: | + | | style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:">35 days</span></span></span></p> |
| − | | style="width:76.5pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family: | + | | style="width:76.5pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:">?</span></span></span></p> |
| − | | style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family: | + | | style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:">Reduced</span></span></span></p> |
| − | | style="width:66.05pt; border:solid windowtext 1.0pt" width="91" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family: | + | | style="width:66.05pt; border:solid windowtext 1.0pt" width="91" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:">P <0.05</span></span></span></p> |
|- | |- | ||
| style="width:146.35pt; border:solid windowtext 1.0pt" width="198" | | | style="width:146.35pt; border:solid windowtext 1.0pt" width="198" | | ||
| − | <span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family: | + | <span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">Serum soluble interleukin 2 receptor</span></span>'''</span> |
| − | | style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family: | + | | style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:">35 days</span></span></span></p> |
| − | | style="width:76.5pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family: | + | | style="width:76.5pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:">?</span></span></span></p> |
| − | | style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family: | + | | style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:">Not increased</span></span></span></p> |
| − | | style="width:66.05pt; border:solid windowtext 1.0pt" width="91" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family: | + | | style="width:66.05pt; border:solid windowtext 1.0pt" width="91" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:">P <0.05</span></span></span></p> |
|- | |- | ||
| style="width:146.35pt; border:solid windowtext 1.0pt" width="198" | | | style="width:146.35pt; border:solid windowtext 1.0pt" width="198" | | ||
| − | <span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family: | + | <span style="line-height:normal">'''<span style="font-size:12.0pt"><span style="font-family:">Plasma fibronectin</span></span>'''</span> |
| − | | style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family: | + | | style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:">35 days</span></span></span></p> |
| − | | style="width:76.5pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family: | + | | style="width:76.5pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:">?</span></span></span></p> |
| − | | style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family: | + | | style="width:76.45pt; border:solid windowtext 1.0pt" width="104" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:">Not decreased</span></span></span></p> |
| − | | style="width:66.05pt; border:solid windowtext 1.0pt" width="91" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family: | + | | style="width:66.05pt; border:solid windowtext 1.0pt" width="91" | <p align="center" style="margin-bottom:.0001pt; text-align:center; padding:.75pt .75pt .75pt .75pt"><span style="line-height:normal"><span style="font-size:12.0pt"><span style="font-family:">P < 0.01</span></span></span></p> |
|} | |} | ||
| − | | + | |
| − | '''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Comments:</span>''' | + | '''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Comments:</span>''' |
<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">1. Abstract only, little data given.</span> | <span style="font-family: 'Times New Roman','serif'; font-size: 16px;">1. Abstract only, little data given.</span> | ||
| Line 63: | Line 71: | ||
<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">5. Article in Chinese, not yet available in translation.</span> | <span style="font-family: 'Times New Roman','serif'; font-size: 16px;">5. Article in Chinese, not yet available in translation.</span> | ||
| − | ''' | + | '''''''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Appraised by:</span>''''' ''<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Mike Bennett and Juliette Leverment, Hyperbaric Medicine, Prince of Wales Hospital, Sydney ; Monday, 9 December 2002</span> |
<span style="font-family: 'Times New Roman','serif'; font-size: 16px;">'''Email:''' m.bennett@unsw.edu.au </span> <span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Kill or Update By: December 2024</span> | <span style="font-family: 'Times New Roman','serif'; font-size: 16px;">'''Email:''' m.bennett@unsw.edu.au </span> <span style="font-family: 'Times New Roman','serif'; font-size: 16px;">Kill or Update By: December 2024</span> | ||
Latest revision as of 21:42, 9 October 2021
Hyperbaric oxygenation may have reduced the incidence of sepsis associated with thermal burns.
Clinical Bottom Line:
1. Apparent reduction in the incidence of sepsis following thermal burns with the addition of hyperbaric oxygenation to a therapeutic regime.
Citation: 1. Xu N, Li Z, Luo X. [Effects of hyperbaric oxygen therapy on the changes in serum sIL-2R and Fn in severe burn patients]. Zhonghua Zheng Xing Shao Shang Wai Ke Za Zhi 1999; 15(3):220-223. Lead author's name and fax:
Three-part Clinical Question: For patients with thermal burns, does the addition of hyperbaric oxygenation to a standard therapeutic regimen reduce the incidence of burn infection?
Search Terms: Hyperbaric oxygenation, Burns thermal
The Study: Non-blinded randomised controlled trial with intention-to-treat unknown.
Study Patients: Patients with >30% body surface area burns (or 3rd degree >10%BSA).
Control group (N = 17): Not stated
Experimental group (N = 25): HBO regimen not stated
The Evidence:
|
Non-Event Outcomes |
Time to outcome |
Control group |
HBO group |
P-value |
|
Incidence of sepsis |
35 days |
? |
Reduced |
P <0.05 |
|
Serum soluble interleukin 2 receptor |
35 days |
? |
Not increased |
P <0.05 |
|
Plasma fibronectin |
35 days |
? |
Not decreased |
P < 0.01 |
Comments:
1. Abstract only, little data given.
2. No details of randomization method, control therapy or hyperbaric schedule.
3. Clinical impact unknown.
4. Soluble interleukin 2 receptors in the serum are increased and plasma fibronectin is decreased in patients with burns and they are both apparently markers for burn infection. These markers were not significantly different in HBO treated subjects when compared to healthy, non-burned controls.
5. Article in Chinese, not yet available in translation.
Appraised by: Mike Bennett and Juliette Leverment, Hyperbaric Medicine, Prince of Wales Hospital, Sydney ; Monday, 9 December 2002
Email: m.bennett@unsw.edu.au Kill or Update By: December 2024
